Details:
The Company will use the proceeds for clinical and pre-clinical testing of company's product candidates, including MEAI (5-methoxy-2-aminoindane), a novel psychoactive molecule which reduce the desire to consume alcoholic beverages.
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Nutrition and Weight Loss Product Name: MEAI
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Aegis Capital Corp.
Deal Size: $2.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 18, 2023
Details:
The Company will use the proceeds for clinical and pre-clinical testing of company's product candidates, including MEAI (5-methoxy-2-aminoindane), a novel psychoactive molecule which reduce the desire to consume alcoholic beverages.
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Nutrition and Weight Loss Product Name: MEAI
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Aegis Capital Corp.
Deal Size: $2.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 14, 2023
Details:
The collaboration aims to evaluate Clearmind's and SciSparc's combination treatment of MEAI (5-methoxy-2-aminoindane), a novel proprietary psychedelic treatment, and PEA (phenethylamine), the active ingredient of CannAmide, for obesity and metabolic syndrome.
Lead Product(s): 5-Methoxy-2-Aminoindane,Palmitoylethanolamide
Therapeutic Area: Nutrition and Weight Loss Product Name: CMND-100
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Hebrew University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 16, 2023
Details:
CMND-100 (5-methoxy-2-aminoindane), which is Clearmind’s lead compound, is a novel psychedelic-derived drug candidate, exhibiting compelling evidence that suggests a significant reduction of desire to consume alcoholic beverages- addressing a global unmet need.
Lead Product(s): 5-Methoxy-2-Aminoindane,CannAmide
Therapeutic Area: Nutrition and Weight Loss Product Name: CMND-100
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2023
Details:
The animals treated with MEAI (5-methoxy-2-aminoindane) showed increased energy expenditure, better fat utilization and weight loss of 20%, while reducing their overall fat mass and preserving their lean body mass. No effect on motivation and well-being was observed.
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Nutrition and Weight Loss Product Name: MEAI
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
The partnership will focus on the early-stage development of glycerol-3-phosphate phosphatase (G3PP) activators.The treatment aims to prevent and reverse the adverse effects of excess sugar and caloric intake and to promote healthier aging.
Lead Product(s): Undisclosed
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Paraza Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 20, 2021